Operator: Good afternoon ladies and gentlemen and welcome to the Hologic Incorporated Fourth Quarter and Fiscal 2012 Earnings Conference Call. My name is Kelsey and I am your operator for today's conference. Today's conference call is being recorded. All lines have been placed on mute.
I will now turn the conference over to Deborah Gordon, Vice President, Investor Relations. Please go ahead, Ms. Gordon.
Deborah R. Gordon - VP, IR: Thank you, Kelsey. Good afternoon and thank you for joining us for Hologic's fourth quarter and fiscal 2012 earnings conference call.
The replay of this call will be archived on our website through Friday, November 30th. A copy of our press release discussing our fourth quarter and fiscal year results, as well as our first quarter and fiscal 2013 guidance is available on the overview section of the investor relation page of Hologic's website. Also in that section is the PowerPoint presentation related to the comments that will be made during today's opening remarks.
Before we begin, I would like to inform you that certain statements made by Hologic's during the course of this call may constitute forward-looking statements. These statements involve known and unknown risks and uncertainties that may cause the actual results to be materially different from any future results implied by such statements. Such factors include those referenced in our Safe Harbor statements and our fourth quarter fiscal 2012 earnings release and in the Company's filings with the Securities and Exchange Commission.
Also, during this call we will be discussing certain financial measures not prepared in accordance with generally accepted accounting principles or GAAP. A reconciliation of these non-GAAP financial measures to the related GAAP financial measures can also be found in our fourth quarter earnings releases, including the financial tables in the release.
Please note today's call will consist of 30 minutes of opening remarks, followed by a 30 minute Q&A session. We do need to limit each participant's questions to just one with one related follow-up as necessary. However, please feel free to go back into queue and if time permits we will be more than happy to take your questions at that time.
Lastly, I would like to remind you of our upcoming investor meeting at RSNA in Chicago, during which we will discuss Tomo from a commercial and an economical perspective. The event will take place on Tuesday, November 27, beginning at 8 am Central Time. You may access the live webcast of the event on our IR website.
I would now like to turn the call over to Rob Cascella, President and Chief Executive Officer.
Robert A. Cascella - President and CEO: Thanks, Deb. Good afternoon and thanks for dialing into our fourth quarter earnings call. Joining me on call today are Glenn Muir, our Executive Vice President and Chief Financial Officer; Carl Hull General Manager of our Diagnostics business, Peter Soltani, General Manager of our Breast Health business and David Harding, General Manager of International Operations.
Today, I'll summarize our fourth quarter performance. I'm also going to update you on the integration of Gen-Probe, including our expectations for synergies, review the market adoption of our Dimensions 3D tomo system and provide a brief review of some of the other key business. Glenn will then give you a financial review in greater detail and introduce you to our first quarter and fiscal 2013 guidance. We'll then open up the call for 30 minutes for Q&A.